Table 3 Clinical parameters, treatments, and outcomes of patients hospitalized due to COVID-19 at Mount Sinai Hospital
Subset of patients treated at Mount Sinai hospital for which full clinical data was available | Hospitalized patients total | Hospitalized patients alive | Hospitalized patients deceased | |||
|---|---|---|---|---|---|---|
n = 23 | n = 16 | n = 7 | ||||
Clinical presentation | ||||||
 Fever | 70% | (16) | 69% | (11) | 71% | (5) |
 Systolic BP < 90 mmHg | 9% | (2) | 0% | (0) | 29% | (2) |
 MAP < 65 mmHg | 9% | (2) | 0% | (0) | 29% | (2) |
 Heart rate > 100 bpm | 48% | (11) | 56% | (9) | 29% | (2) |
 RR > 20/min | 26% | (6) | 19% | (3) | 43% | (3) |
 Oxygen requirement at presentation | ||||||
  None | 57% | (13) | 69% | (11) | 29% | (2) |
  Nasal cannula or NRB mask | 30% | (7) | 25% | (4) | 43% | (3) |
  High-flow oxygen, CPAP, or BiPAP | 4% | (1) | 0% | (0) | 14% | (1) |
  Mechanical ventilation | 9% | (2) | 6% | (1) | 14% | (1) |
Treatment initiated | ||||||
 Remdesivir | 4% | (1) | 6% | (1) | 0% | (0) |
 Hydroxychloroquine | 74% | (17) | 69% | (11) | 86% | (6) |
 Azithromycin | 74% | (17) | 75% | (12) | 71% | (5) |
 Other antibiotics | 83% | (19) | 81% | (13) | 86% | (6) |
 G-CSF | 26% | (6) | 38% | (6) | 0% | (0) |
 Therapeutic anticoagulation | 78% | (18) | 69% | (11) | 100% | (7) |
 Systemic corticosteroids | 43% | (10) | 31% | (5) | 71% | (5) |
 Anti-TNF | 4% | (1) | 0% | (0) | 14% | (1) |
 Anti-IL-1 | 9% | (2) | 0% | (0) | 29% | (2) |
 Anti-IL-6 | 17% | (4) | 13% | (2) | 29% | (2) |
 Selinexor | 22% | (5) | 25% | (4) | 14% | (1) |
 Convalescent plasma | 4% | (1) | 6% | (1) | 0% | (0) |
Complications | ||||||
 Highest level of oxygen requirement | ||||||
  None | 26% | (6) | 31% | (5) | 14% | (1) |
  Nasal cannula or NRB mask | 39% | (9) | 56% | (9) | 0% | (0) |
  High-flow oxygen, CPAP, or BiPAP | 13% | (3) | 6% | (1) | 29% | (2) |
  Mechanical ventilation | 22% | (5) | 6% | (1) | 57% | (4) |
 ICU | 30% | (7) | 6% | (1) | 86% | (6) |
 Acute kidney injury | 52% | (12) | 38% | (6) | 86% | (6) |
 Shock | 30% | (7) | 0% | (0) | 100% | (7) |
 Sepsis or HAP/VAP | 9% | (2) | 6% | (1) | 14% | (1) |
 C. difficile infection | 4% | (1) | 6% | (1) | 0% | (0) |
 Cardiac complication | 30% | (7) | 19% | (3) | 57% | (4) |
Worst biochemical parameters | ||||||
 CRP | 151.5 | [178.1] | 144.9 | [107.7] | 294.1 | [132.9] |
 Total leukocyte count (× 10e9/L) (lowest) | 3.3 | [2.6] | 2.9 | [2.4] | 4.3 | [8.4] |
 Absolute lymphocyte count (× 10e9/L) (lowest) | 0.3 | [0.4] | 0.4 | [0.5] | 0.2 | [0.2] |
 Creatinine (mg/dL) | 1.6 | [2.4] | 1.1 | [1.4] | 2.7 | [2] |
 Procalcitonin (ng/mL) | 0.8 | [2.1] | 0.5 | [0.8] | 2.7 | [9.9] |
 Ferritin (μg/L) | 2537 | [2578] | 1282 | [2170.5] | 3409 | [2018] |
 Fibrinogen (mg/dL) | 667 | [167] | 646 | [209.5] | 673.5 | [43.8] |
 D-dimer (mg/L) | 2.5 | [14.3] | 2 | [2.6] | 20 | [7.6] |
 LDH (U/L) | 531.5 | [515.8] | 478 | [329] | 739 | [344] |
 ALT (U/L) | 61 | [58.5] | 43.5 | [52.8] | 79 | [32] |
 AST (U/L) | 78 | [62.5] | 49.5 | [54.3] | 101 | [51.5] |
 IL-1β (pg/mL) | 0.5 | [0.9] | 0.5 | [0.8] | 0.5 | [0.9] |
 IL-6 (pg/mL) | 128.5 | [211.6] | 119.3 | [102.4] | 296.8 | [821.2] |
 IL-8 (pg/mL) | 65.4 | [62.3] | 46.6 | [67.6] | 137 | [89.6] |
 TNF-alfa (pg/mL) | 28.7 | [11] | 29.4 | [8.4] | 21.3 | [15.2] |